Skip to main content
. 2021 Apr 23;9:580118. doi: 10.3389/fchem.2021.580118

Figure 1.

Figure 1

Distribution of the reviewed publications between 2013 and 2020 on NLCs and SLNs, by therapeutic field: anticancer therapies (41.8%, light blue); various indications (16.7%, gray); antimicrobials (14.3%, pink); CNS diseases, excluding cancer and infection (12.4%, green); nanovehicles not intended for any specific therapeutic area (7.5%, yellow); and site-specific treatments (7.3%, dark blue). Reproduced with permission from Frontiers in Molecular Biosciences (Montoto et al., 2020).